MTYEKA

Live / Applied — Fourth extension granted (statement of use) (as of 28 May 2025)

What this means for you

Not registered yet, but its 08 Mar 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.

Record

Serial number
97301650
Mark type
Stylized text
Filed
08 Mar 2022
Published for opposition
02 May 2023
Attorney of record
Marilyn F. Kelly

Goods and services

  • Class 005 — Pharmaceuticals: pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for use in oncology; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of bladder cancer; pharmaceutical preparations for the treatment of lung cancer; pharmaceutical preparations for the treatment of renal cancer; pharmaceutical preparations for the treatment of renal cell carcinoma; pharmaceutical preparations for the treatment of squamous cell carcinoma; pharmaceutical preparations for the treatment of head and neck squamous cell carcinoma; pharmaceutical preparations for the treatment of oral cavity squamous cell carcinoma; pharmaceutical preparations for the treatment of colorectal cancer; pharmaceuticals comprising small molecules for the treatment of cancer; pharmaceuticals comprising small molecules for the treatment of bladder cancer; pharmaceuticals comprising small molecules for the treatment of lung cancer; pharmaceuticals comprising small molecules for the treatment of renal cancer; pharmaceuticals comprising small molecules for the treatment of renal cell carcinoma; pharmaceuticals comprising small molecules for the treatment of squamous cell carcinoma; pharmaceuticals comprising small molecules for the treatment of head and neck squamous cell carcinoma; pharmaceuticals comprising small molecules for the treatment of oral cavity squamous cell carcinoma; pharmaceuticals comprising small molecules for the treatment of colorectal cancer; pharmaceutical products for the treatment of cancer; pharmaceutical products for use in oncology; pharmaceutical products for the treatment of infectious diseases; pharmaceutical products for the treatment of bladder cancer; pharmaceutical products for the treatment of lung cancer; pharmaceutical products for the treatment of renal cancer; pharmaceutical products for the treatment of renal cell carcinoma; pharmaceutical products for the treatment of squamous cell carcinoma; pharmaceutical products for the treatment of head and neck squamous cell carcinoma; pharmaceutical products for the treatment of oral cavity squamous cell carcinoma; pharmaceutical products for the treatment of colorectal cancer; pharmaceuticals comprising compounds for the treatment of cancer; pharmaceuticals comprising inhibitors for the treatment of cancer; pharmaceuticals for the treatment of solid tumors
  • Class 042 — Scientific and technological services: research and development of pharmaceuticals in the field of oncology; providing information in the field of scientific and medical research related to oncology; research and development of pharmaceuticals; providing information in the field of scientific and medical research related to pharmaceuticals

Owner

Prosecution history

  • 12 Nov 2025 — SOU TEAS EXTENSION RECEIVED
  • 15 Sept 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
  • 28 May 2025 — SOU EXTENSION 4 GRANTED
  • 28 May 2025 — SOU EXTENSION 4 FILED
  • 28 May 2025 — SOU TEAS EXTENSION RECEIVED
  • 02 Apr 2025 — ASSIGNED TO EXAMINER
  • 03 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
  • 25 Nov 2024 — SOU EXTENSION 3 GRANTED
  • 25 Nov 2024 — SOU EXTENSION 3 FILED
  • 25 Nov 2024 — SOU TEAS EXTENSION RECEIVED
  • 27 Jun 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
  • 27 Jun 2024 — SOU EXTENSION 2 GRANTED
  • 27 Jun 2024 — SOU EXTENSION 2 FILED
  • 27 Jun 2024 — SOU TEAS EXTENSION RECEIVED
  • 27 Jun 2024 — TEAS CHANGE OF CORRESPONDENCE RECEIVED

View this trademark record on Marksy